Literature DB >> 18614315

Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.

Francis F Arhin1, Karla Tomfohrde, Deborah C Draghi, Mohana Aranza, Thomas R Parr, Daniel F Sahm, Gregory Moeck.   

Abstract

A 9-laboratory M23-A2 quality control (QC) study was performed to evaluate reproducibility of oritavancin MICs against reference strains of Staphylococcus aureus, Enterococcus faecalis, and Streptococcus pneumoniae using broth microdilution assays in the presence of polysorbate 80. Polysorbate 80 has previously been shown to be required for accurate measurement of oritavancin broth microdilution MICs. Greater than 95% of replicate results (n = 270/organism) fell within the following QC ranges (in micrograms per milliliter): S. aureus ATCC 29213, 0.015 to 0.12; E. faecalis ATCC 29212, 0.008 to 0.03; and S. pneumoniae ATCC 49619, 0.001 to 0.004. Oritavancin MIC QC ranges were, thus, narrow and reproducible. Parameters affecting testing results in the presence of polysorbate 80 were also evaluated. Oritavancin MICs were equivalent to or within 1 doubling dilution of those obtained under standard Clinical and Laboratory Standards Institute testing conditions, regardless of incubation time (18, 24, or 48 h), Ca(2+) concentration, pH, or frozen panel storage time (up to 6 months).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614315     DOI: 10.1016/j.diagmicrobio.2008.05.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Authors:  Ronald N Jones; John D Turnidge; Greg Moeck; Francis F Arhin; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

Authors:  David J Farrell; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

3.  Evaluation of Non-Tissue Culture- versus Tissue Culture-Treated Microplates for Oritavancin Susceptibility Testing.

Authors:  Qun Yan; Melissa J Karau; Robin Patel
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 4.  Antimicrobial Susceptibility Testing for Enterococci.

Authors:  Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias
Journal:  J Clin Microbiol       Date:  2022-06-13       Impact factor: 11.677

Review 5.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

6.  Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.

Authors:  James E Ross; Rodrigo E Mendes; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

7.  Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.

Authors:  Angela Kavanagh; Soumya Ramu; Yujing Gong; Matthew A Cooper; Mark A T Blaskovich
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.